Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa
-
* Corresponding author: Alain Nahum nahum_alain@yahoo.fr
Malaria Journal 2007, 6:170 doi:10.1186/1475-2875-6-170
Accesses
- Last 30 days: 58 accesses
- Last year: 356 accesses
- All time: 2791 accesses
Cited by
BioMed Central: 3 citations
|
Research
Maryline Bonnet, Ingrid van den Broek, Michel van Herp, Pedro Urrutia, Chantal van Overmeir, Juliet Kyomuhendo, Célestin Ndosimao, Elizabeth Ashley, Jean-Paul Guthmann Malaria Journal 2009, 8:192 (10 August 2009) The finding of varying efficacy of the same combinations at two sites in one country highlights one difficulty of implementing a uniform national treatment policy in a large country. The poor efficacy of AS+AQ in Boende should alert the national programme to foci of resistance and emphasizes the need for systems for the prospective monitoring of treatment efficacy at sentinel sites in the country.
|
|
Research
Issaka Sagara, Stephen Rulisa, Wilfred Mbacham, Ishag Adam, Kourane Sissoko, Hamma Maiga, Oumar B Traore, Niawanlou Dara, Yahia T Dicko, Alassane Dicko, Abdoulaye Djimdé, F Herwig Jansen, Ogobara K Doumbo Malaria Journal 2009, 8:63 (14 April 2009) This multicenter study comparing two regimens of a new
co-formulated artemisinin-based therapy and a standard regimen of artemether-lumefantrine for the treatment of uncomplicated malaria in Africa. This large and comprehensive study presents a compelling case for consideration of the new
co-formulated AS-SMP regimen for the treatment of uncomplicated malaria.
|
|
Research
Alain Nahum, Annette Erhart, Daniel Ahounou, Désiré Bonou, Chantal Van Overmeir, Joris Menten, Martin Akogbeto, Marc Coosemans, Achille Massougbodji, Umberto D'Alessandro Malaria Journal 2009, 8:37 (3 March 2009) The paper describes an extended follow-up study of efficacy of SP plus artesunate, which is a response to the concern that the new ACT drug strategy is inefficient when artemisinin is combined with a partner drug in a situation where resistance to the partner drug is prevalent.
|